Answers are grounded in this paper and cite their sources.
Tirzepatide is associated with a dose-dependent increase in incidence of GI AEs and AEs leading to drug discontinuation. Severe hypoglycemia, fatal AEs, acute pancreatitis, cholelithiasis, and cholecystitis are rare with this medication.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: